12:00 AM
 | 
Apr 27, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Factor X coagulation product: Phase III data

Bio Products Laboratory said the criteria for treatment success were met in an open-label Phase III trial in 16 patients with severe or moderate hereditary Factor X deficiency evaluating the company’s Factor X coagulation product. Of 187 evaluable bleed in the trial, patients rated 170...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >